Journal
JOURNAL OF MEDICINAL CHEMISTRY
Volume 55, Issue 22, Pages 9810-9816Publisher
AMER CHEMICAL SOC
DOI: 10.1021/jm3010338
Keywords
-
Categories
Funding
- Swiss National Science Foundation [K-32K1-120904]
- Swiss National Science Foundation (SNF) [K-32K1-120904] Funding Source: Swiss National Science Foundation (SNF)
Ask authors/readers for more resources
Mannose-based FimH antagonists are considered new therapeutics for the treatment of urinary tract. infections (UTIs). They prevent the adhesion of uropathogenic Escherichia coli (UPEC) to urothelial cell surfaces triggered by the lectin FimH, which is located at the tip of bacterial type I pili. Because all reported FimH antagonists are alpha-D-mannosides, they are also potential ligands of mannose receptors of the human host system. We therefore investigated the selectivity range of five FimH antagonists belonging to different compound families by comparing their affinities for FimH and eight human mannose receptors. On the basis of the detected selectivity range of approximately 5 orders of magnitude, no adverse side effects resulting from nonselective binding to the human receptors have to be expected. FimH antagonists can therefore be further considered as potential therapeutics for the., treatment of UTI.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available